Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK5757 · 1 trial · 1 indication
The Brief Assessment of Cognition in Schizophrenia (BACS) was used to evaluate cognitive impairment, as measured by the mean change from baseline after 2 weeks of treatment in the composite score. The BACS composite score was calculated by averaging scores from the BACS subtests, including Verbal Memory, Digit Sequencing, Token Motor, Symbol Coding, Verbal Fluency (Semantic Fluency and Letter Fluency) and Tower of London. The possible minimum and maximum scores for change from baseline at two weeks of treatment for the endpoint are -111.5 and 111.5, respectively.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK5757 |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| MK5757 | DRUG | This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 25 mg capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 MK5757 50 mg capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days |
| Comparator: Placebo | DRUG | This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 one placebo capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 two MK5757 placebo capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days. |
Inclusion Criteria: * Patient is male between 21 and 55 years of age * Duration of the illness must be longer than 1 year * Patient's current antipsychotic medication regimen must be stable * Patient is negative for selected drugs of abuse at Screening * Must be in a stable living arrangement for a...
MK5757 is an investigational small molecule being studied for the treatment of cognitive impairment in men with schizophrenia. It is in Phase 2 clinical development and is not yet approved by the FDA. The drug is being developed by Merck & Company, Inc. (MRK).
The specific molecular target of MK5757 has not been disclosed in the available information. The drug is a small molecule being investigated for its potential to treat cognitive impairment associated with schizophrenia, but its mechanism of action is not publicly detailed.
MK5757 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 2 clinical trials for schizophrenia-related cognitive impairment.
MK5757 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for the treatment of cognitive impairment in men with schizophrenia, and its Phase 2 trial has been completed.
MK5757 has one completed Phase 2 clinical trial registered as NCT00848484, titled 'Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)'. This randomized, double-blind, placebo-controlled study enrolled 54 male participants aged 21 years and older with schizophrenia.
No alternative names for MK5757 have been disclosed in the available information. The drug is identified solely by its development code MK5757 and is being studied by Merck & Company, Inc. for cognitive impairment in schizophrenia.